The NDA is based on data from the CAPItello-291 Phase III trial presented at the 2022 San Antonio Breast Cancer Symposium and recently published ...
News
- Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in ... - BioSpace
- Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP ... - BioSpace
... the Society for Neuro-Oncology annual meeting, the San Antonio Breast Cancer Symposium, and the Frontiers in Drug Discovery Journal.
- Magic cocktail generates lung's most critical immune cell in the lab - Newswise
Newswise — SAN ANTONIO (June 12, 2023) — Researchers at Texas Biomedical Research Institute have succeeded in generating the lung's most important ...
- Rockville biotech OpGen faces delisting threat from Nasdaq - Washington Business Journal
... YorkOrlandoPhiladelphiaPhoenixPittsburghPortlandProvidenceRaleigh/DurhamSacramentoSan AntonioSan FranciscoSeattleSilicon ValleySt. LouisTampa ...
- $158 Million Renovation to Commence on InterContinental San Antonio, City's Newest Luxury Hotel
Renovation to Encompass Sophisticated Rooms and Unparalleled Amenities SAN ANTONIO, June 12, 2023 /PRNewswire-PRWeb/ -- Scarlett Hotel Group (SHG) ...